vs
Journey Medical Corp（DERM）与Dominari Holdings Inc.（DOMH）财务数据对比。点击上方公司名可切换其他公司
Dominari Holdings Inc.的季度营收约是Journey Medical Corp的1.9倍（$30.1M vs $16.1M），Journey Medical Corp净利率更高（-7.8% vs -438.1%，领先430.4%），Dominari Holdings Inc.同比增速更快（220.4% vs 27.3%），过去两年Dominari Holdings Inc.的营收复合增速更高（369.1% vs 11.0%）
Journey Medical Corp是一家处于商业化阶段的生物制药企业，专注于皮肤病治疗领域，研发、生产并销售处方及非处方皮肤用药，覆盖痤疮、特应性皮炎、皮肤真菌感染等适应症，主要服务美国市场的医疗机构与患者。
DERM vs DOMH — 直观对比
营收规模更大
DOMH
是对方的1.9倍
$16.1M
营收增速更快
DOMH
高出193.1%
27.3%
净利率更高
DERM
高出430.4%
-438.1%
两年增速更快
DOMH
近两年复合增速
11.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $16.1M | $30.1M |
| 净利润 | $-1.2M | $-131.8M |
| 毛利率 | — | — |
| 营业利润率 | -2.8% | -8.9% |
| 净利率 | -7.8% | -438.1% |
| 营收同比 | 27.3% | 220.4% |
| 净利润同比 | -182.0% | -12426.2% |
| 每股收益（稀释后） | $-0.04 | $-6.94 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DERMDOMH
| Q4 25 | $16.1M | $30.1M | ||
| Q3 25 | $17.0M | $50.8M | ||
| Q2 25 | $15.0M | $34.1M | ||
| Q1 25 | $13.1M | $8.1M | ||
| Q4 24 | $12.6M | $9.4M | ||
| Q3 24 | $14.6M | $4.0M | ||
| Q2 24 | $14.9M | $6.2M | ||
| Q1 24 | $13.0M | $1.4M |
净利润DERMDOMH
| Q4 25 | $-1.2M | $-131.8M | ||
| Q3 25 | $-2.3M | $125.2M | ||
| Q2 25 | $-3.8M | $16.6M | ||
| Q1 25 | $-4.1M | $-32.5M | ||
| Q4 24 | $1.5M | $1.1M | ||
| Q3 24 | $-2.4M | $-4.2M | ||
| Q2 24 | $-3.4M | $-6.1M | ||
| Q1 24 | $-10.4M | $-5.4M |
毛利率DERMDOMH
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 82.3% | — | ||
| Q3 24 | 63.9% | — | ||
| Q2 24 | 56.0% | — | ||
| Q1 24 | 47.7% | — |
营业利润率DERMDOMH
| Q4 25 | -2.8% | -8.9% | ||
| Q3 25 | -9.0% | -3.1% | ||
| Q2 25 | -19.2% | -57.0% | ||
| Q1 25 | -25.3% | -394.6% | ||
| Q4 24 | 17.7% | 0.4% | ||
| Q3 24 | -19.8% | -79.1% | ||
| Q2 24 | -19.7% | -44.3% | ||
| Q1 24 | -77.4% | -205.2% |
净利率DERMDOMH
| Q4 25 | -7.8% | -438.1% | ||
| Q3 25 | -13.6% | 246.4% | ||
| Q2 25 | -25.3% | 48.7% | ||
| Q1 25 | -31.0% | -400.5% | ||
| Q4 24 | 12.1% | 11.4% | ||
| Q3 24 | -16.3% | -104.2% | ||
| Q2 24 | -22.6% | -99.1% | ||
| Q1 24 | -80.1% | -398.0% |
每股收益（稀释后）DERMDOMH
| Q4 25 | $-0.04 | $-6.94 | ||
| Q3 25 | $-0.09 | $7.27 | ||
| Q2 25 | $-0.16 | $1.12 | ||
| Q1 25 | $-0.18 | $-3.02 | ||
| Q4 24 | $0.10 | $0.21 | ||
| Q3 24 | $-0.12 | $-0.67 | ||
| Q2 24 | $-0.17 | $-1.01 | ||
| Q1 24 | $-0.53 | $-0.91 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $24.1M | $80.5M |
| 总债务越低越好 | $25.3M | — |
| 股东权益账面价值 | $31.9M | $69.4M |
| 总资产 | $94.6M | $112.9M |
| 负债/权益比越低杠杆越低 | 0.79× | — |
8季度趋势，按日历期对齐
现金及短期投资DERMDOMH
| Q4 25 | $24.1M | $80.5M | ||
| Q3 25 | $24.9M | $176.2M | ||
| Q2 25 | $20.3M | $28.2M | ||
| Q1 25 | $21.1M | $18.9M | ||
| Q4 24 | $20.3M | $8.2M | ||
| Q3 24 | $22.5M | $7.2M | ||
| Q2 24 | $23.9M | $12.1M | ||
| Q1 24 | $24.1M | $7.1M |
总债务DERMDOMH
| Q4 25 | $25.3M | — | ||
| Q3 25 | $25.2M | — | ||
| Q2 25 | $25.1M | — | ||
| Q1 25 | $25.0M | — | ||
| Q4 24 | $24.9M | — | ||
| Q3 24 | $19.8M | — | ||
| Q2 24 | $19.7M | — | ||
| Q1 24 | $14.7M | — |
股东权益DERMDOMH
| Q4 25 | $31.9M | $69.4M | ||
| Q3 25 | $25.9M | $210.2M | ||
| Q2 25 | $19.2M | $88.6M | ||
| Q1 25 | $21.5M | $42.4M | ||
| Q4 24 | $20.1M | $39.9M | ||
| Q3 24 | $10.9M | $38.3M | ||
| Q2 24 | $11.3M | $42.4M | ||
| Q1 24 | $13.0M | $47.7M |
总资产DERMDOMH
| Q4 25 | $94.6M | $112.9M | ||
| Q3 25 | $85.2M | $223.4M | ||
| Q2 25 | $81.2M | $109.3M | ||
| Q1 25 | $85.0M | $52.3M | ||
| Q4 24 | $80.2M | $47.1M | ||
| Q3 24 | $64.0M | $43.4M | ||
| Q2 24 | $65.2M | $49.1M | ||
| Q1 24 | $66.6M | $52.2M |
负债/权益比DERMDOMH
| Q4 25 | 0.79× | — | ||
| Q3 25 | 0.97× | — | ||
| Q2 25 | 1.30× | — | ||
| Q1 25 | 1.16× | — | ||
| Q4 24 | 1.24× | — | ||
| Q3 24 | 1.81× | — | ||
| Q2 24 | 1.75× | — | ||
| Q1 24 | 1.13× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-6.3M | $22.7M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流DERMDOMH
| Q4 25 | $-6.3M | $22.7M | ||
| Q3 25 | $-2.4M | $-4.9M | ||
| Q2 25 | $-942.0K | $-353.0K | ||
| Q1 25 | $-2.8M | $1.2M | ||
| Q4 24 | $2.2M | $-16.7M | ||
| Q3 24 | $-1.2M | $-4.7M | ||
| Q2 24 | $-5.2M | $1.4M | ||
| Q1 24 | $-5.0M | $-8.6M |
现金转化率DERMDOMH
| Q4 25 | — | — | ||
| Q3 25 | — | -0.04× | ||
| Q2 25 | — | -0.02× | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.46× | -15.65× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
DOMH
| Chief Operating Decision Maker | $30.1M | 100% |
| Commissions | $458.0K | 2% |
